TARSUS PHARMACEUTICALS TARS 深 沪
等待开盘 11-05 09:30:00 美东时间
71.50
+1.710
+2.45%
华盛通- 最 高71.645
- 今 开67.82
- 成交量 82.52万股
- 最 低 67.75
- 昨 收 69.79
- 总市值 30.18亿
- 52周最高 76.81
- 市盈率 静 --
- 换手率 1.95%
- 52周最低 38.51
- 委 比 -72.74%
- 总股本 4221.41万
- 历史最高 76.81
- 量 比 1.95
- 振 幅 5.58%
- 历史最低 10.80
- 每 手 1
- 风险率 7.88%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Tarsus Pharmaceuticals shares are trading lower. The company reported Q3 financial results.
Tarsus Pharmaceuticals shares are trading lower. The company reported Q3 financ...
今天 06:10
Earnings Scheduled For November 4, 2025
Companies Reporting Before The Bell • Sequans Communications (NYSE:SQNS) is lik...
11-04 19:12
美股大行评级 | 潜在涨幅344.44%！Rani Therapeutics获Maxim Group升目标价至10美元，维持"买入"评级
今日重点评级关注：Maxim Group：维持Rani Therapeutics Hldgs"买入"评级，目标价从5美元升至10美元；韦德布什：维持Corbus Pharmaceuticals"跑赢大市"评级，目标价从31美元升至38美元
10-21 18:13
HC Wainwright & Co. Maintains Buy on Tarsus Pharmaceuticals, Raises Price Target to $88
HC Wainwright & Co. analyst Matthew Caufield maintains Tarsus Pharmaceuticals (NASDAQ:TARS) with a Buy and raises the price target from $72 to $88.
10-20 18:40
Top 2 Health Care Stocks That May Fall Off A Cliff In August
As of Aug. 20, 2025, two stocks in the health care sector could be flashing a r...
08-20 20:46
Tarsus targets 95,000–100,000 bottles for Q3 2025 amid accelerated XDEMVY launch momentum
Earnings Call Insights: Tarsus Pharmaceuticals (TARS) Q2 2025 Management View CEO Bobak R. Azamian highlighted that "we delivered record-breaking results of more than $100 million in net sales and app...
08-07 15:04
Tarsus Pharmaceuticals Reports Record Sales Growth
Tarsus Pharmaceuticals, Inc. ( ($TARS) ) has released its Q2 earnings. Here is ...
08-07 12:54
Earnings Scheduled For August 6, 2025
Companies Reporting Before The Bell • Lineage (NASDAQ:LINE) is likely to report...
08-06 16:33
Tarsus to Report Second Quarter 2025 Financial Results on Wednesday, August 6, 2025
Tarsus Pharmaceuticals, Inc. will host a live webcast on August 6, 2025, at 1:30 p.m. PT / 4:30 p.m. ET, to discuss its second quarter 2025 financial results and provide a corporate update. Participants can access the webcast via the provided link. A recorded version will be available on the company's website for 90 days. Tarsus focuses on advancing treatments for eye care and infectious diseases, with FDA-approved XDEMVY® for Demodex blepharitis...
07-30 21:00
多轮破亿元资金注入人形机器人赛道，资本更青睐“汽车人”造“人”？
本报（chinatimes.net.cn）记者于建平 见习记者 黄蓓 北京报道 在汽车企业掌门人们还在为确保现金流充足，不断降本增效的同时，另一群从汽车产业出走...
07-23 21:05
